Tatyana Matveeva, PhD
Mass General Hospital
Director of CGMP Operations, Regenerative Cell Therapy, Neurosurgery
Tatyana Matveeva, PhD, Director of cGMP Operations, Cell Therapy,
Neurosurgery, Mass General Hospital
Neurodegenerative conditions are prevalent and devastating diseases with severe economic, personal, and healthcare expense consequences. Cell replacement therapies have offered a route to functional recovery, but clinical cell manufacturing frequently requires distributed production and oversight associated with substantial financial burden. The present report will outline an in-hospital cGMP cell manufacturing facility with adjacent quality control and in direct proximity to patients, and demonstrate the challenges of developing a compliant and all-inclusive program at cost.
Neurosurgery, Mass General Hospital
Neurodegenerative conditions are prevalent and devastating diseases with severe economic, personal, and healthcare expense consequences. Cell replacement therapies have offered a route to functional recovery, but clinical cell manufacturing frequently requires distributed production and oversight associated with substantial financial burden. The present report will outline an in-hospital cGMP cell manufacturing facility with adjacent quality control and in direct proximity to patients, and demonstrate the challenges of developing a compliant and all-inclusive program at cost.